| HOME >> BIOLOGY >> TECHNOLOGY |
PARIS, August 26 /PRNewswire-FirstCall/ --
- Net Profit Up 11%
- Strong Research and Investment Effort
- Positive net Financial Position
- Annual Growth Guidance Maintained at 10%
The Board of Directors, meeting on 25 August 2009 under the chairmanship of Albert Saporta approved the 2009 half year financial statements:
In million Euros H1 2008 08/07 H1 2009
%CA Var.% %CA
Sales 87.0 100.0 16 97.6 100.0
Cost of goods sold (19.9) (22.8) 18 (22.5) (23.1)
SG&A (35.1) (40.3) 12 (37.8) (38.8)
R&D net (13.7) (15.7) 22 (17.7) (18.1)
EBIT 18.4 21.1 19 19.6 20.1
Net result, group 12.0 13.8 19 13.4 13.7
share
EBITDA 21.5 24.8 14 24.1 24.7
Capital expenditure (4.9) (5.6)(21) (9.4) (9.6)
Free cash flow 10.0 11.5 43 14.5 14.8
Net financial debts 4.2 4.9 (54) (1.3) (1.4)
Equity 75.4 86.6 29 92.9 95.2
EPS, diluted 0.90 EUR 19 1.01 EUR
Dividend rate 39% -1580% 35%
Dividend per share 0.35 EUR - 0.35 EUR
(continued)
In million Euros 09/08 B 2009 09/08 OL1 2009
Var.% % Var.%
Sales 12 185.0 100.0 8 187.7
Cost of goods sold 13 (44.2) (23.9) 11 (44.4)
SG&A 8 (77.7) (42.0) 7 (78.0)
R&D net 29 (34.2) (18.5) 14 (36.3)
EBIT 7 29.0 15.6 3 29.0
Net result, gro
'/>"/>
| SOURCE Stallergenes Copyright©2009 PR Newswire. All rights reserved |